US6306914B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Progestin therapy for maintaining amenorrhea
Assignee: COLUMBIA LOBORATORIES Inc
•
Filing: 1998-10-13
•
Granted: 2001-10-23
•
Expires: 2018-10-13
Abstract
Abstract The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.
Inventors
- 👤 Dominique de Ziegler
- 👤 William J. Bologna
- 👤 Howard L. Levine
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K9/00; A61K9/0012; A61K9/0034; A61P; A61P15/00; A61P15/12; A61P15/18; A61P5/00; A61P5/24; A61P5/34; A61K47/00; A61K47/30; A61K47/32; A61K9/70; A61K9/7023
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
64 words
A method of maintaining amenorrhea in a woman undergoing constant progestin administration comprising constant vaginal administration of progestin via a drug delivery system in an amount sufficient to cause endometrial atrophy within the first month of administration and to maintain endometrial atrophy without causing the side effects encountered with progestin administration: wherein the drug delivery system comprises a water-soluble, water-swellable cross-linked polycarboxylic acid polymer.
Claim 2
Independent Claim
64 words
A method of maintaining amenorrhea in a woman undergoing constant progestin administration comprising constant vaginal administration of progestin via a drug delivery system in an amount sufficient to cause endometrial atrophy within the first month of administration and to maintain endometrial atrophy without causing the side effects encountered with progestin administration: wherein the drug delivery system comprises a water-soluble, water-swellable cross-linked polycarboxylic acid polymer.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the polymer is polycarbophil.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein the progestin is administered about twice per week.
Claim 5
Dependent Claim
14 words
The method of claim 2 wherein the progestin is administered about twice per week.
Claim 6
Dependent Claim
10 words
The method of claim 1 wherein the progestin is progesterone.
Claim 7
Dependent Claim
10 words
The method of claim 2 wherein the progestin is progesterone.
Claim 8
Dependent Claim
21 words
The method of claim 5 wherein the amount of progesterone delivered is about 45 mg to about 90 mg per dose.
Claim 9
Dependent Claim
21 words
The method of claim 6 wherein the amount of progesterone delivered is about 45 mg to about 90 mg per dose.
Claim 10
Dependent Claim
16 words
The method of claim 5 wherein the drug delivery system additionally comprises at least one adjuvant.
Claim 11
Dependent Claim
16 words
The method of claim 6 wherein the drug delivery system additionally comprises at least one adjuvant.
Claim 12
Dependent Claim
14 words
The method of claim 2 wherein the woman is also being treated with estrogen.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-10-22 | 2005-04-23 | 2005-10-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-10-22 | 2009-04-23 | 2009-10-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-10-22 | 2013-04-23 | 2013-10-23 | $7700.00 | Window Closed / Lapsed |